Kamada Ltd. (KMDA)
Price:
7.02 USD
( + 0.01 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Viatris Inc.
VALUE SCORE:
5
2nd position
Neurocrine Biosciences, Inc.
VALUE SCORE:
9
The best
Amphastar Pharmaceuticals, Inc.
VALUE SCORE:
10
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
NEWS
Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook
benzinga.com
2025-12-08 11:05:09Kamada Ltd. (NASDAQ: KMDA) on Monday said it will discontinue its Phase 3 InnovAATe trial of Inhaled AAT for Alpha-1 Antitrypsin Deficiency (AATD).
Kamada Ltd. (KMDA) Discusses Discontinuation of Phase 3 Inhaled AAT Clinical Trial and Financial Outlook Transcript
seekingalpha.com
2025-12-08 09:26:49Kamada Ltd. (KMDA) Discusses Discontinuation of Phase 3 Inhaled AAT Clinical Trial and Financial Outlook Transcript
Kamada (NASDAQ:KMDA) Share Price Passes Below 200-Day Moving Average – Time to Sell?
defenseworld.net
2025-12-03 03:32:56Kamada Ltd. (NASDAQ: KMDA - Get Free Report)'s share price crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $7.09 and traded as low as $6.89. Kamada shares last traded at $6.92, with a volume of 89,402 shares traded. Wall Street Analysts Forecast Growth Several analysts
Kamada Ltd. (KMDA) Q3 2025 Earnings Call Transcript
seekingalpha.com
2025-11-10 10:51:37Kamada Ltd. ( KMDA ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLC Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division James Sidoti - Sidoti & Company, LLC Presentation Operator Good morning.
Kamada (KMDA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com
2025-11-10 10:30:41While the top- and bottom-line numbers for Kamada (KMDA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Kamada (KMDA) Misses Q3 Earnings Estimates
zacks.com
2025-11-10 09:16:12Kamada (KMDA) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.
Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth
globenewswire.com
2025-11-10 07:00:00REHOVOT, Israel, and HOBOKEN, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three months and nine months ended September 30, 2025.
Should Value Investors Buy Kamada (KMDA) Stock?
zacks.com
2025-11-05 10:40:23Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025
globenewswire.com
2025-11-03 07:00:00REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd.
KMDA vs. NVZMY: Which Stock Is the Better Value Option?
zacks.com
2025-10-31 13:51:27Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Kamada (KMDA) and Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?
Wall Street Analysts Believe Kamada (KMDA) Could Rally 113.15%: Here's is How to Trade
zacks.com
2025-10-30 10:56:10The mean of analysts' price targets for Kamada (KMDA) points to an 113.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
3 Reasons Why Growth Investors Shouldn't Overlook Kamada (KMDA)
zacks.com
2025-10-22 13:46:16Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.
Are Investors Undervaluing Kamada (KMDA) Right Now?
zacks.com
2025-10-20 10:41:02Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
KMDA or ILMN: Which Is the Better Value Stock Right Now?
zacks.com
2025-10-15 12:41:09Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Kamada (KMDA) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
Does Kamada (KMDA) Have the Potential to Rally 114.39% as Wall Street Analysts Expect?
zacks.com
2025-10-14 10:56:09The mean of analysts' price targets for Kamada (KMDA) points to an 114.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"
zacks.com
2025-10-06 13:46:16Kamada (KMDA) could produce exceptional returns because of its solid growth attributes.
Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook
benzinga.com
2025-12-08 11:05:09Kamada Ltd. (NASDAQ: KMDA) on Monday said it will discontinue its Phase 3 InnovAATe trial of Inhaled AAT for Alpha-1 Antitrypsin Deficiency (AATD).
Kamada Ltd. (KMDA) Discusses Discontinuation of Phase 3 Inhaled AAT Clinical Trial and Financial Outlook Transcript
seekingalpha.com
2025-12-08 09:26:49Kamada Ltd. (KMDA) Discusses Discontinuation of Phase 3 Inhaled AAT Clinical Trial and Financial Outlook Transcript
Kamada (NASDAQ:KMDA) Share Price Passes Below 200-Day Moving Average – Time to Sell?
defenseworld.net
2025-12-03 03:32:56Kamada Ltd. (NASDAQ: KMDA - Get Free Report)'s share price crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $7.09 and traded as low as $6.89. Kamada shares last traded at $6.92, with a volume of 89,402 shares traded. Wall Street Analysts Forecast Growth Several analysts
Kamada Ltd. (KMDA) Q3 2025 Earnings Call Transcript
seekingalpha.com
2025-11-10 10:51:37Kamada Ltd. ( KMDA ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLC Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division James Sidoti - Sidoti & Company, LLC Presentation Operator Good morning.
Kamada (KMDA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com
2025-11-10 10:30:41While the top- and bottom-line numbers for Kamada (KMDA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Kamada (KMDA) Misses Q3 Earnings Estimates
zacks.com
2025-11-10 09:16:12Kamada (KMDA) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.
Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth
globenewswire.com
2025-11-10 07:00:00REHOVOT, Israel, and HOBOKEN, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three months and nine months ended September 30, 2025.
Should Value Investors Buy Kamada (KMDA) Stock?
zacks.com
2025-11-05 10:40:23Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025
globenewswire.com
2025-11-03 07:00:00REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd.
KMDA vs. NVZMY: Which Stock Is the Better Value Option?
zacks.com
2025-10-31 13:51:27Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Kamada (KMDA) and Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?
Wall Street Analysts Believe Kamada (KMDA) Could Rally 113.15%: Here's is How to Trade
zacks.com
2025-10-30 10:56:10The mean of analysts' price targets for Kamada (KMDA) points to an 113.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
3 Reasons Why Growth Investors Shouldn't Overlook Kamada (KMDA)
zacks.com
2025-10-22 13:46:16Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.
Are Investors Undervaluing Kamada (KMDA) Right Now?
zacks.com
2025-10-20 10:41:02Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
KMDA or ILMN: Which Is the Better Value Stock Right Now?
zacks.com
2025-10-15 12:41:09Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Kamada (KMDA) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
Does Kamada (KMDA) Have the Potential to Rally 114.39% as Wall Street Analysts Expect?
zacks.com
2025-10-14 10:56:09The mean of analysts' price targets for Kamada (KMDA) points to an 114.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"
zacks.com
2025-10-06 13:46:16Kamada (KMDA) could produce exceptional returns because of its solid growth attributes.